Pliant Therapeutics (PLRX) Cash & Equivalents (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Cash & Equivalents data on file, last reported at $22.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $22.2 million, down 75.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.2 million (down 75.86% YoY), and the FY2025 annual result was $45.4 million, down 36.16% from the prior year.
• Cash & Equivalents eased to $22.2 million in Q1 2026 per PLRX's latest filing, from $45.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $114.3 million in Q1 2024 and troughed at $22.2 million in Q1 2026.
• A 5-year average of $64.7 million and a median of $63.2 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents jumped 215.03% in 2023, then slumped 75.86% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $33.7 million in 2022, then surged by 87.72% to $63.2 million in 2023, then gained by 12.58% to $71.2 million in 2024, then sank by 36.16% to $45.4 million in 2025, then plunged by 51.17% to $22.2 million in 2026.
• Business Quant data shows PLRX's Cash & Equivalents at $22.2 million in Q1 2026, $45.4 million in Q4 2025, and $93.7 million in Q3 2025.